Why the study?
No study had investigated the ability of ankle-brachial index calculated using diastolic blood pressure or mean arterial pressure to predict overall and cardiovascular mortality in hemodialysis patients.
Does calculating ankle-brachial index using diastolic blood pressure and mean arterial pressure predict overall and cardiovascular mortality in hemodialysis patients?
Does calculating ankle-brachial index using diastolic blood pressure and mean arterial pressure predict overall and cardiovascular mortality in hemodialysis patients?
Calculating ankle-brachial index using diastolic blood pressure and mean arterial pressure provides prognostic value for overall and cardiovascular mortality in hemodialysis patients, particularly when standard systolic ABI is normal.
ABIdbp and ABImap may aid mortality prediction in HD patients; leaves open incremental value over standard ABI pending validation.
No study has investigated the predictive ability of ankle-brachial index (ABI) calculated using diastolic blood pressure (DBP) (ABIdbp) and mean arterial pressure (MAP) (ABImap) for overall and cardiovascular (CV) mortality in hemodialysis (HD) patients. Our study was aimed to investigate the issue. Two hundred and seven routine HD patients were enrolled. ABI values were measured by ABI-form device. During the follow-up period (122 months), 124 of the 207 patients (59.0%) died, and 59 deaths due to CV cause. Multivariate analysis showed that low ABIsbp, ABIdbp, and ABImap were all significantly associated with increased overall (p 0.015) and CV mortality (p 0.015) in whole study patients. A subgroup analysis after excluding 37 patients with ABIsbp < 0.9 or > 1.3 found ABIsbp and ABIsbp < 0.9 were not associated with overall and CV mortality. However, ABImap and ABIdbp < 0.87 were significantly associated with overall mortality (p 0.042). Furthermore, ABIdbp and ABIdbp < 0.87 were significantly associated with CV mortality (p 0.030). In conclusion, ABIsbp, ABIdbp, and ABImap were all useful in predicting overall and CV mortality in our HD patients. In the subgroup patients with normal ABIsbp, ABIsbp and ABIsbp < 0.9 were not useful to predict overall and CV mortality. Nevertheless, ABImap and ABIdbp < 0.87 could still predict overall mortality, and ABIdbp and ABIdbp < 0.87 could predict CV mortality. Hence, calculating ABI using DBP and MAP may provide benefit in survival prediction in HD patients, especially in the patients with normal ABIsbp.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: